| breast cancer - HER2-positive | breast cancer - HR positive | |
| la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |
| lapatinib based treatment | ||
| lapatinib plus capecitabine | WJOG6110B/ELTOP | |
| lapatinib plus fulvestrant | CALGB 40302 | |
| lapatinib plus letrozole | EGF30008 ... EGF30008 ... | |
| lapatinib plus trastuzumab | EGF104900 |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
